Castaigne S, Daniel M T, Tilly H, Herait P, Degos L
Blood. 1983 Jul;62(1):85-6.
A series of 21 patients (5 refractory anemias with an excess of blasts in transformation and 16 acute leukemias) were treated with small doses of ARA-C (10 mg/sq m/12 hr for 15-21 days). Improvement was noted in 15 cases (71%) and complete remission observed in 12 (57%). Complete remission was obtained after one course of treatment in 8 cases. The fact that these patients entered remission relatively slowly and did not suffer marrow aplasia suggests that low-dose ARA-C may function in vivo as it does in vitro, i.e., by inducing differentiation of leukemic blasts.
对21例患者（5例转化型原始细胞增多的难治性贫血和16例急性白血病）采用小剂量阿糖胞苷（10mg/平方米/12小时，持续15 - 21天）进行治疗。15例（71%）患者病情有改善，12例（57%）达到完全缓解。8例患者在一个疗程治疗后即获得完全缓解。这些患者进入缓解期相对缓慢且未出现骨髓再生障碍，这一事实表明低剂量阿糖胞苷在体内的作用方式可能与体外相同，即通过诱导白血病原始细胞分化发挥作用。
